BRIEF-Neuropace, Inc. Q1 Revenue USD 22.524 Million Versus. IBES Estimate USD 21.8 Million

Reuters

14 May

BRIEF-Neuropace, Inc. Q1 Revenue USD 22.524 Million Versus. IBES Estimate USD 21.8 Million

May 13 (Reuters) - Neuropace Inc NPCE.O:

NEUROPACE, INC. Q1 REVENUE USD 22.524 MILLION VERSUS. IBES ESTIMATE USD 21.8 MILLION
NEUROPACE, INC. Q1 INCOME FROM OPERATIONS USD -5.147 MILLION VERSUS. IBES ESTIMATE USD -6.43 MILLION
NEUROPACE, INC. Q1 GROSS PROFIT USD 17.342 MILLION
NEUROPACE, INC. Q1 OPERATING EXPENSES USD 22.489 MILLION
NEUROPACE, INC. Q1 EPS USD -0.21 VERSUS. IBES ESTIMATE USD -0.24
NEUROPACE, INC. Q1 NET INCOME USD -6.589 MILLION VERSUS. IBES ESTIMATE USD -7.66 MILLION
NEUROPACE, INC. OUTLOOK FY REVENUE USD 93-97 MILLION
NEUROPACE, INC. OUTLOOK FY GROSS MARGIN 73-75%

Source text: ID:nGNX6BDFTm

Further company coverage: NPCE.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2535087165"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535087165\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535087165?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 04:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535087165","market":"us","top_or_hot":-1,"title":"BRIEF-Neuropace, Inc. Q1 Revenue USD 22.524 Million Versus. IBES Estimate USD 21.8 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Neuropace, Inc. Q1 Revenue USD 22.524 Million Versus. IBES Estimate USD 21.8 Million</title></head><body><p><span>May 13 (Reuters)</span><span> - </span>Neuropace Inc <span>NPCE.O</span>:</p><ul><li><p>NEUROPACE, INC. Q1 REVENUE USD 22.524 MILLION VERSUS. IBES ESTIMATE USD 21.8 MILLION</p></li><li><p>NEUROPACE, INC. Q1 INCOME FROM OPERATIONS USD -5.147 MILLION VERSUS. IBES ESTIMATE USD -6.43 MILLION</p></li><li><p>NEUROPACE, INC. Q1 GROSS PROFIT USD 17.342 MILLION</p></li><li><p>NEUROPACE, INC. Q1 OPERATING EXPENSES USD 22.489 MILLION</p></li><li><p>NEUROPACE, INC. Q1 EPS USD -0.21 VERSUS. IBES ESTIMATE USD -0.24</p></li><li><p>NEUROPACE, INC. Q1 NET INCOME USD -6.589 MILLION VERSUS. IBES ESTIMATE USD -7.66 MILLION</p></li><li><p>NEUROPACE, INC. OUTLOOK FY REVENUE USD 93-97 MILLION</p></li><li><p>NEUROPACE, INC. OUTLOOK FY GROSS MARGIN 73-75%</p></li></ul><p>Source text: <span>ID:nGNX6BDFTm</span></p><p>Further company coverage: <span>NPCE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Neuropace, Inc. Q1 Revenue USD 22.524 Million Versus. IBES Estimate USD 21.8 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Neuropace, Inc. Q1 Revenue USD 22.524 Million Versus. IBES Estimate USD 21.8 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-14 04:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Neuropace, Inc. Q1 Revenue USD 22.524 Million Versus. IBES Estimate USD 21.8 Million</title></head><body><p><span>May 13 (Reuters)</span><span> - </span>Neuropace Inc <span>NPCE.O</span>:</p><ul><li><p>NEUROPACE, INC. Q1 REVENUE USD 22.524 MILLION VERSUS. IBES ESTIMATE USD 21.8 MILLION</p></li><li><p>NEUROPACE, INC. Q1 INCOME FROM OPERATIONS USD -5.147 MILLION VERSUS. IBES ESTIMATE USD -6.43 MILLION</p></li><li><p>NEUROPACE, INC. Q1 GROSS PROFIT USD 17.342 MILLION</p></li><li><p>NEUROPACE, INC. Q1 OPERATING EXPENSES USD 22.489 MILLION</p></li><li><p>NEUROPACE, INC. Q1 EPS USD -0.21 VERSUS. IBES ESTIMATE USD -0.24</p></li><li><p>NEUROPACE, INC. Q1 NET INCOME USD -6.589 MILLION VERSUS. IBES ESTIMATE USD -7.66 MILLION</p></li><li><p>NEUROPACE, INC. OUTLOOK FY REVENUE USD 93-97 MILLION</p></li><li><p>NEUROPACE, INC. OUTLOOK FY GROSS MARGIN 73-75%</p></li></ul><p>Source text: <span>ID:nGNX6BDFTm</span></p><p>Further company coverage: <span>NPCE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nPLX1800E2:1","article_id":"2535087165","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535087165","pubTimestamp":1747168916,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Neuropace, Inc. Q1 Revenue USD 22.524 Million Versus. IBES Estimate USD 21.8 MillionMay 13 (Reuters) - Neuropace Inc NPCE.O:NEUROPACE, INC. Q1 REVENUE USD 22.524 MILLION VERSUS. IBES ESTIMATE US","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"简介-Neuropace，Inc.第一季度收入为2252.4万美元。IBES估计为2180万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NPCE":0.9},"content_text":"BRIEF-Neuropace, Inc. Q1 Revenue USD 22.524 Million Versus. IBES Estimate USD 21.8 MillionMay 13 (Reuters) - Neuropace Inc NPCE.O:NEUROPACE, INC. Q1 REVENUE USD 22.524 MILLION VERSUS. IBES ESTIMATE USD 21.8 MILLIONNEUROPACE, INC. Q1 INCOME FROM OPERATIONS USD -5.147 MILLION VERSUS. IBES ESTIMATE USD -6.43 MILLIONNEUROPACE, INC. Q1 GROSS PROFIT USD 17.342 MILLIONNEUROPACE, INC. Q1 OPERATING EXPENSES USD 22.489 MILLIONNEUROPACE, INC. Q1 EPS USD -0.21 VERSUS. IBES ESTIMATE USD -0.24NEUROPACE, INC. Q1 NET INCOME USD -6.589 MILLION VERSUS. IBES ESTIMATE USD -7.66 MILLIONNEUROPACE, INC. OUTLOOK FY REVENUE USD 93-97 MILLIONNEUROPACE, INC. OUTLOOK FY GROSS MARGIN 73-75%Source text: ID:nGNX6BDFTmFurther company coverage: NPCE.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}